title: Hematologic malignancies in the Japanese patients with inflammatory bowel disease.
abstract: BACKGROUND
  Although attention has been focused for over 20 years on the possible increased risk for hematologic malignancies (HM) in patients with inflammatory bowel diseases (IBD) receiving immune-modulators or anti-TNF-alpha antibodies, the association is still controversial. To understand the actual conditions of HM in the Japanese patients with IBD, the research committee for IBD supported by the Ministry of Health, Welfare and Labor of Japan (IBD-MHWL) conducted a multi-center retrospective study.
  
  
  METHODS
  Questionnaires for the development of HM in IBD patients were sent to the 70 facilities participating with IBD-MHWL in the first survey, followed by the second survey using a more detailed questionnaire, sent to the 27 members with HM patients.
  
  
  RESULTS
  Out of a total of 36,939 IBD patients in 70 facilities, 28 cases of HM related with IBD [12 of 10,500 UC patients (0.11 %), 16 of 6,310 CD patients (0.25 %)] were analyzed. The numbers of UC patients who developed HM were 2 (0.15 %) from the group receiving and 10 (0.13 %) from the group non-receiving thiopurine, without significant differences. The numbers of CD patients who developed HM were 4 (0.39 %) from the group receiving and 12 (0.21 %) from the group non-receiving thiopurine, without significant differences. The odds ratios of developing HM by thiopurine were 1.37 (95 % CI 0.30-6.24) in UC patients and 1.86 (95 % CI 0.60-5.78) in CD patients.
  
  
  CONCLUSIONS
  Our results suggested that thiopurine therapy may not be a risk factor for HM in Japanese patients with IBD. Further accumulation of cases and prospective studies are necessary to conclude this important issue.
authors: Department of Gastroenterology and Hepatology, Kansai Medical University, Hirakata, Japan.
authors: Norimasa
authors: N
authors: Fukata
authors: Kazuichi
authors: K
authors: Okazaki
authors: Mika
authors: M
authors: Omiya
authors: Mitsunobu
authors: M
authors: Matsushita
authors: Mamoru
authors: M
authors: Watanabe
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D003424:Crohn Disease / Q000188:drug therapy*; D019337:Hematologic Neoplasms / Q000453:epidemiology* / Q000209:etiology; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007564:Japan; D008297:Male; D008875:Middle Aged; D011687:Purines / Q000009:adverse effects / Q000627:therapeutic use; D012189:Retrospective Studies; D012307:Risk Factors; D011795:Surveys and Questionnaires; D055815:Young Adult
chemical_list: D007166:Immunosuppressive Agents; D011687:Purines
references: Am J Gastroenterol. 2010 Jul;105(7):1480-7
references: 20332773
references: Lancet. 2012 Jun 9;379(9832):2212
references: 22682468
references: Lancet. 2009 Nov 7;374(9701):1617-25
references: 19837455
references: Am J Gastroenterol. 1999 Apr;94(4):1047-52
references: 10201481
references: Gut. 2000 Oct;47(4):514-9
references: 10986211
references: Cancer. 2001 Feb 15;91(4):854-62
references: 11241255
references: Dis Colon Rectum. 2007 Jun;50(6):839-55
references: 17308939
references: Clin Lymphoma Myeloma Leuk. 2010 Apr;10(2):144-8
references: 20371449
references: Cancer. 1991 Apr 1;67(7):2015-9
references: 2004319
references: Am J Gastroenterol. 2000 Sep;95(9):2308-12
references: 11007233
references: Jpn J Clin Oncol. 2011 Jan;41(1):139-47
references: 20819836
references: Gut. 2005 Aug;54(8):1121-5
references: 16009685
references: Acta Haematol. 2012;128(1):1-6
references: 22572218
references: Jpn J Clin Oncol. 2012 Feb;42(2):139-47
references: 22172347
references: J Gastroenterol Hepatol. 2013 Aug;28(8):1300-5
references: 23488881
references: Lancet. 1994 May 21;343(8908):1249-52
references: 7910274
references: Inflamm Bowel Dis. 2011 Sep;17(9):1837-45
references: 21830262
references: Leuk Lymphoma. 1995 Apr;17(3-4):255-62
references: 8580794
references: J Gastroenterol. 2012 Jan;47(1):1-8
references: 22215058
references: J Clin Gastroenterol. 2005 Jan;39(1):21-6
references: 15599205
references: Clin Gastroenterol Hepatol. 2004 Dec;2(12):1088-95
references: 15625654
references: Aliment Pharmacol Ther. 2002 Jul;16(7):1225-32
references: 12144571
references: Am J Gastroenterol. 1999 Nov;94(11):3248-53
references: 10566724
references: Gut. 2005 May;54(5):617-22
references: 15831904
references: Am J Med. 1985 Jan 21;78(1A):44-9
references: 3970040
references: J Rheumatol. 2007 Feb;34(2):322-31
references: 17117491
references: Gastroenterology. 2001 Nov;121(5):1080-7
references: 11677199
references: Gastroenterology. 1994 Dec;107(6):1675-9
references: 7958678
references: Aliment Pharmacol Ther. 2004 Feb 1;19(3):287-93
references: 14984375
references: Eur J Haematol. 2013 Jul;91(1):20-8
references: 23560463
references: J Gastroenterol. 2013 Jan;48(1):31-72
references: 23090001
references: Rev Esp Enferm Dig. 2009 Apr;101(4):288-94
references: 19492906
references: Inflamm Bowel Dis. 2007 Oct;13(10):1299-307
references: 17600819
references: Gastroenterology. 2000 Sep;119(3):647-53
references: 10982757
references: Gut. 2009 Oct;58(10):1427-36
references: 19749141